1. Wilkins L. The diagnosis and treatment of endocrine disorders in children and adolescence. Springfield: Charles Thomas; 1965. p. 141–50.
2. Abraham-Nordling M, Torring O, Lantz M, Hallengren B, Ohrling H, Lundell G, et al. Incidence of hyperthyroidism in Stockholm, Sweden, 2003–2005. Eur J Endocrinol. 2008;158(6):823–7.
3. Jacobson DL, Gange SJ, Rose NR, Graham NM. Epidemiology and estimated population burden of selected autoimmune diseases in the United States. Clin Immunol Immunopathol. 1997;84(3):223–43.
4. Conference Proceeding: Hepatic toxicity following treatment for pediatric Graves’ disease meeting: October 28, 2008. Eunice Kennedy Shriver National Institute of Child Health and Human Development.
http://bpca.nichd.nih.gov/outreach/index.cfm
. 2009 [January 14, 2009]; Available from:
http://bpca.nichd.nih.gov/outreach/index.cfm
.
5. Smith J, Brown RS. Persistence of thyrotropin (TSH) receptor antibodies in children and adolescents with Graves’ disease treated using antithyroid medication. Thyroid. 2007;17(11):1103–7.